Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase

The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 pip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2003-01, Vol.13 (2), p.277-280
Hauptverfasser: Stelmach, John E., Liu, Luping, Patel, Sangita B., Pivnichny, James V., Scapin, Giovanna, Singh, Suresh, Hop, Cornelis E.C.A., Wang, Zhen, Strauss, John R., Cameron, Patricia M., Nichols, Elizabeth A., O'Keefe, Stephen J., O'Neill, Edward A., Schmatz, Dennis M., Schwartz, Cheryl D., Thompson, Chris M., Zaller, Dennis M., Doherty, James B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-α production in LPS-stimulated whole blood (IC 50=10 nM) and good oral exposure in rats (F=68%, AUCn PO=0.58 μM h). Graphic
ISSN:0960-894X
1464-3405
DOI:10.1016/S0960-894X(02)00752-7